﻿For most EGFR-mutant NSCLC patients with third-generation EGFR TKIs treatment, resistance arises after a dramatic initial response to EGFR TKIs followed by stable minimal residual disease and subsequent development of drug-resistant tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.